Take a look

Conference Abstract: 89Zr chelate evaluation

In vitro and in vivo evaluation of novel 89Zr-chelators

Rene Raave, Gerwin Sandker, Sandra Heskamp, Otto Boerman, Mark Rijpkema, Floriane Mangin, Michel Meyer, Jean-Claude Chambron, Mathieu Moreau, Claire Bernhard, Adrien Dubois, Laurene Da Costa, Victor Goncalves, Franck Denat

Third international edition of the symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM 2018), September 26-29, 2018, Bressanone (BZ), Italy


The current “gold standard” chelator to label antibodies with 89Zr for immunoPET is desferrioxamine (DFO).1 Preclinical studies have shown that the 89Zr-DFO complex is partly unstable in vivo, resulting in release of 89Zr and subsequent accumulation in mineral bone. This bone uptake may prevent the detection of bone metastases, and hampers accurate estimation of the radiation dose to the bone marrow in dose planning for radioimmunotherapy. Therefore, there is a need for more stable 89Zr chelators.